A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of PF-08052666/SGN-MesoC2 in Participants With Advanced Solid Tumors
Latest Information Update: 24 May 2025
At a glance
- Drugs HBM-9033 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Colorectal cancer; Lung cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Harbour BioMed; Seagen
Most Recent Events
- 23 May 2025 According to a Nona Biosciences media release, data from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 21 Feb 2025 Planned End Date changed from 1 Nov 2028 to 16 Feb 2029.
- 21 Feb 2025 Planned primary completion date changed from 1 Nov 2028 to 17 Feb 2028.